This is a major regulatory de-risking for RCKT's lead cardiovascular gene therapy program. The clear path to a 12-patient pivotal study with preserved accelerated approval endpoints removes significant uncertainty. Traders should watch for the October 6, 2026 webinar for further data updates and monitor enrollment progress toward the mid-2027 dosing completion target.
Price Chart
Executive Summary
Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed a 12-patient pivotal population at a recalibrated dose, with the first three patients already treated counting toward that total, and preserved 12-month co-primary endpoints intended to support potential accelerated approval. This removes a key regulatory overhang and provides a clear path to enrollment completion by mid-2027, a significant de-risking event for the program.
Key Facts
- FDA confirmed continued enrollment and dosing under the modified protocol at the recalibrated dose of 3.8 × 10^13 GC/kg.
- Pivotal study population set at 12 male patients; first three patients treated count toward this total, leaving nine to enroll.
- Rocket expects to complete dosing of remaining patients by mid-2027.
- Co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index at 12 months are preserved to support potential accelerated approval.
- No clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome observed in the first three patients.
- A comprehensive Danon disease program webinar is scheduled for October 6, 2026.
Financial Impact
No financial data provided in the filing. The event de-risks a pivotal gene therapy program for Danon disease, a rare and life-threatening condition with no approved therapies, representing a potential multi-hundred-million to billion-dollar peak sales opportunity if approved.
Risk Factors
- The pivotal trial is small (12 patients) and efficacy/safety results remain binary; a miss on co-primary endpoints at 12 months would be devastating.
- Manufacturing scale-up for commercial-grade product and long-term durability of LAMP2 expression are unproven.
- The company is pre-revenue and will require additional capital to fund operations through potential approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-036563 |
| Document: ef20082010_ex99-1.htm | 0001140361-26-036563 |
| Document: 0001140361-26-036563-index-headers.html | 0001140361-26-036563 |
| Document: 0001140361-26-036563-index.html | 0001140361-26-036563 |
| Document: 0001140361-26-036563.txt | 0001140361-26-036563 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $3.41 $3.35 | ▼ −1.76% | ▼ −3.89% | $2.56 (−24.93%) |
Aug 20, 2026 6w ago | Insider Cluster | $3.48 $3.62 | ▲ +4.02% | ▲ +2.91% | $2.56 (−26.44%) |
Aug 17, 2026 6w ago | Insider Cluster | $3.34 $3.78 | ▲ +13.17% | ▲ +13.37% | $2.56 (−23.35%) |
Aug 13, 2026 7w ago | Insider Cluster | $3.34 $3.48 | ▲ +4.04% | ▲ +6.01% | $2.56 (−23.35%) |
Aug 10, 2026 7w ago | 8-K | $3.50 $3.34 | ▼ −4.57% | ▼ −4.17% | $2.56 (−26.86%) |
Aug 3, 2026 8w ago | 8-K | $3.41 $3.64 | ▲ +6.74% | ▲ +4.72% | $2.56 (−24.93%) |
Jun 30, 2026 13w ago | 8-K | $3.52 $4.07 | ▲ +15.63% | ▲ +15.36% | $2.56 (−27.27%) |
Jun 12, 2026 16w ago | 8-K | $2.75 $3.35 | ▲ +21.82% | ▲ +21.15% | $2.56 (−6.91%) |
May 26, 2026 18w ago | Insider Cluster | $2.99 $2.92 | ▼ −2.34% | ▼ −2.81% | $2.56 (−14.38%) |
May 7, 2026 21w ago | Insider Cluster | $3.25 $2.96 | ▼ −8.92% | ▼ −9.89% | $2.56 (−21.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access